Revenue Performance - Revenue for Q3 2025 decreased by $3.9 million, or 20.6%, to $15.1 million from $19.0 million in Q3 2024[5] - Device revenue declined by 26% to $11.7 million, while service revenue grew by 4% to $3.1 million compared to the prior year[10] - The company reiterated its full-year revenue guidance for fiscal year 2025, expecting revenue between $60 million and $67 million[12] Profit and Loss - Gross profit for Q3 2025 was $7.2 million, a decrease of 30.4% year-over-year, primarily due to lower sales in the EMEA region[7] - Net income for the three months ended December 31, 2025, was a loss of $3,728 thousand, compared to a profit of $2,969 thousand for the same period in 2024, representing a significant decline[23] - Comprehensive loss for the nine months ended December 31, 2024, was $6,496 thousand, compared to a loss of $2,616 thousand for the same period in 2023, indicating a worsening financial position[23] - The company reported a net loss of $4,272 thousand for the nine months ended December 31, 2024, compared to a net loss of $2,428 thousand for the same period in 2023, reflecting increased operational challenges[26] Expenses - Selling, general and administrative expenses increased by $2.8 million, or 50.6%, to $8.2 million, driven by higher employee compensation and overhead costs[8] - Research and development costs rose by $0.1 million, or 7.7%, to $1.8 million, mainly due to increased amortization expenses[9] - The company incurred depreciation and amortization expenses of $611 thousand for the nine months ended December 31, 2024, compared to $230 thousand for the same period in 2023, highlighting increased asset utilization[26] - The company reported stock compensation expenses of $450 thousand for the nine months ended December 31, 2024, compared to no such expenses in the same period of 2023, reflecting changes in compensation strategy[26] Cash Flow and Liquidity - Cash and cash equivalents as of December 31, 2024, totaled $1.1 million[11] - Cash flows from operating activities for the nine months ended December 31, 2024, resulted in a net cash outflow of $848 thousand, compared to a cash inflow of $3,177 thousand for the same period in 2023[26] - Cash, cash equivalents, and restricted cash at the end of the period were $1,120 thousand, down from $3,225 thousand at the beginning of the period, indicating liquidity challenges[26] Equity and Inventory Management - Total equity decreased to $(37,882) thousand as of December 31, 2024, from $(34,395) thousand as of September 30, 2024, indicating a decline in shareholder value[24] - The allowance for inventory obsolescence was $(67) thousand for the nine months ended December 31, 2024, a significant change from $705 thousand in the same period of 2023, suggesting improved inventory management[26] Other Financial Metrics - The impact of foreign currency translation gain was $0.2 million for Q3 2025[6] - The effect of currency translation on cash and cash equivalents was a gain of $5 thousand for the nine months ended December 31, 2024, consistent with the previous year[26] - The company closed a public offering yielding gross proceeds of approximately $4.6 million, with net proceeds of about $3.9 million after expenses[13] - Collaborations with Nobis Rehabilitation Partners and Zahrawi Group were announced, expanding the distribution network[10]

Financial Performance - DIH generated revenue of $35.1 million for the six months ended September 30, 2024, a 34.5% increase compared to $26.1 million for the same period in 2023[108]. - Revenue for the three months ended September 30, 2024 increased by $5.1 million, or 39.1%, to $18.2 million from $13.1 million for the same period in 2023, primarily driven by a $4.9 million increase in device sales[128]. - Devices revenue for the six months ended September 30, 2024 increased by $8.0 million, or 39.0%, to $28.6 million compared to $20.6 million for the same period in 2023[130]. - Gross profit for the three months ended September 30, 2024 was $9.6 million, representing a 76.7% increase from $5.4 million in the same period in 2023[127]. - Operating income for the three months ended September 30, 2024 was $1.9 million, a significant improvement from an operating loss of $2.5 million in the same period in 2023[127]. - Net loss for the three months ended September 30, 2024 was $234,000, a 90.6% improvement from a net loss of $2.5 million in the same period in 2023[127]. - The net loss for the six months ended September 30, 2024, was $0.5 million, significantly improved from a net loss of $5.4 million in the prior year, reflecting a $4.9 million improvement driven by an $8.2 million increase in gross profit[109]. Expenses and Costs - Selling, general and administrative expenses are expected to rise as the company scales its workforce and enhances support functions to meet public company demands[122]. - Research and development costs are projected to increase as DIH invests in product design and technology to drive business growth[123]. - Selling, general, and administrative expenses for the three months ended September 30, 2024 decreased by $0.6 million, or 9.6%, to $5.8 million from $6.4 million in the same period in 2023[135]. - Research and development costs for the three months ended September 30, 2024 increased by $0.3 million, or 20.6%, to $1.9 million compared to $1.6 million in the same period in 2023[137]. - Total operating expenses for the three months ended September 30, 2024 decreased by $287,000, or 3.6%, to $7.7 million compared to $8.0 million in the same period in 2023[127]. Cash Flow and Financing - The company had cash and cash equivalents of $1.8 million as of September 30, 2024, down from $3.2 million as of March 31, 2024[143]. - The company experienced negative cash flows from operating activities of $(1.5) million during the six months ended September 30, 2024[143]. - Net cash used in operating activities increased by $3.3 million to $(1.5) million for the six months ended September 30, 2024, compared to $1.8 million for the same period in 2023[150]. - Net cash provided by financing activities increased by $4.5 million to $0.8 million for the six months ended September 30, 2024, compared to $(3.7) million for the same period in 2023, primarily due to $2.8 million proceeds from convertible debt financing[151]. - Company continues to explore financing alternatives in debt or equity to fund ongoing operations and fulfill current obligations[146]. - Company expects to fund future cash flows used in investing activities with cash flow generated by operations[150]. - Company anticipates sources of liquidity to include cash on hand and cash flow from operations[146]. Business Developments - The company completed a business combination on February 7, 2024, which included Hocoma Medical, enhancing its asset base and operational capabilities[110]. - DIH issued $3.3 million in principal amount of convertible debentures on June 6, 2024, with a conversion price of $5.00 per share, resulting in net proceeds of approximately $2.8 million[113]. - The company expects to incur additional annual expenses as a public company, including increased costs for directors' and officers' liability insurance and compliance-related expenses[111]. Market Outlook - DIH anticipates revenue growth in future periods due to expanding demand for its rehabilitation products in represented markets[119]. - Cost of sales is expected to increase in absolute dollars as orders grow, while cost per unit is projected to decrease due to improved leverage[120]. - The company faces ongoing challenges from global macroeconomic factors, including supply chain disruptions and inflationary pressures, which could impact future operations[118]. Working Capital - Net decrease of $8.0 million in working capital was driven by a decrease of $4.3 million in advanced payments from customers for the six months ended September 30, 2024, compared to the same period in 2023[154]. - The remaining balance on related party notes payable is $9.4 million and $11.5 million as of September 30, 2024, and March 31, 2024, respectively[144]. - Company incurred three related party notes payable to Hocoma AG totaling $19.84 million, due on June 30, 2026, with an interest rate of 1.25%[144]. - Non-cash charges decreased by $0.1 million for the six months ended September 30, 2024, compared to the same period in 2023[153].

Exhibit 99.1 DIH Announces Second Quarter 2025 Financial Results and Restates June 30, 2024 Form 10-Q NORWELL, MA – November 14, 2024 DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporates visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced fi ...

Exhibit 99.1 DIH Announces Fiscal 2025 First Quarter Financial Results NORWELL, MA – August 19, 2024 DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced financial results for the quarter en ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock DHAI The Nasdaq Stock Market LLC Warrants DHAIW The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Revenue and Market Dependence - The company relies heavily on its key product lines, with LokoMat accounting for over 45% of revenue and other key products (Erigo, Armeo, C-Mill, and CAREN/Grail) collectively contributing 55%[77]. - Approximately 90% of the company's revenue is generated from its current key product lines, which are critical for its financial success[75]. - 80% of the company's revenue is concentrated in the EMEA and Americas regions, indicating a significant reliance on these markets[77]. Economic and Regulatory Risks - The company faces risks related to economic conditions, including potential decreases in demand due to economic slowdowns, inflation, and increased interest rates[78]. - The company has not yet substantiated the long-term health benefits of its products through large randomized clinical trials, which may limit market adoption[98]. - Regulatory compliance is critical, as failure to meet FDA and international standards could result in product recalls or inability to market products[122]. - The new Medical Device Regulation (MDR) in the EU introduces additional compliance challenges that could affect product approval timelines[124]. - Legislative and regulatory healthcare reforms may lead to decreased reimbursement for medical devices, impacting the company's ability to market and generate sales[135]. Operational Challenges - The company is dependent on the successful training of customers and clinicians for the effective use of its products, which is critical for achieving expected growth[90]. - The company may face challenges in maintaining its sales and marketing infrastructure, which is essential for expanding its market presence and product adoption[96]. - Manufacturing delays due to raw material shortages, labor disputes, and regulatory compliance failures could adversely impact the business[101]. - The company relies on sole source third-party manufacturers for certain raw materials and products, which poses risks of supply interruptions and potential revenue loss[100]. - The company faces challenges in managing growth, which could limit its ability to increase sales and cash flow if not addressed properly[121]. Financial Performance and Growth - The company recorded revenue of approximately $64 million for the year ended March 31, 2024[179]. - Total revenue for the year ended March 31, 2024, was $64,473,000, an increase of 19.9% compared to $54,059,000 for the year ended March 31, 2023[298]. - The net loss for the year ended March 31, 2024, was $8,443,000, compared to a net loss of $1,014,000 for the year ended March 31, 2023, representing a significant increase in losses[298]. - Total assets increased to $35,735,000 as of March 31, 2024, compared to $31,779,000 as of March 31, 2023, reflecting a growth of 12.5%[298]. - The company anticipates significant growth, which will require enhanced operational and financial systems to manage effectively[120]. Capital and Financing - The company may need to raise additional capital to fund growth and operations, which could dilute shareholder value if equity is sold[84]. - The Company plans to fund its growth through cash flows from operations and future debt and equity financing[322]. - The Company may issue up to 6,000,000 Earnout Shares based on the volume-weighted average price of DIH Common Stock reaching certain thresholds during the Earnout Period[317]. Compliance and Legal Risks - The company must comply with various privacy and data protection laws, such as the CCPA and GDPR, which could increase compliance costs and liabilities[140]. - The risk of litigation or claims related to acquired companies could increase operational costs and divert management focus[119]. - The company faces risks related to potential patent infringement claims, especially for products acquired through acquisitions[164]. Management and Internal Controls - The company has identified material weaknesses in its internal control over financial reporting, particularly due to limited accounting personnel, which could impact the accuracy and timeliness of financial reporting[197]. - The management team has limited experience managing a public company, which may affect the company's ability to comply with regulatory obligations and manage day-to-day operations effectively[194]. - The anticipated growth may strain the management team and financial resources, potentially leading to misallocation of resources and operational weaknesses[192]. Market and Competitive Landscape - The fragmented rehabilitation technology market presents both opportunities for consolidation and challenges in changing customer mindsets[104]. - The company faces volatility in its common stock price due to various factors, including fluctuations in growth rates and competition from new technologies[181]. - Political changes in the United States or Europe could significantly impact the company’s sales performance and growth projects[152]. Product and Warranty Management - The Company estimates warranty costs based on the number of units sold and historical claim rates, adjusting recorded warranty liabilities quarterly as necessary[338]. - The Company recognizes revenue primarily at the point in time when the customer obtains control, typically coinciding with delivery and customer acceptance[337]. - The Company assesses the adequacy of its recorded warranty liabilities on a quarterly basis and adjusts these amounts as necessary[338].

Financial Overview - ATAK completed a public offering of 20,200,000 Units, raising approximately $200 million, with each Unit consisting of one Class A ordinary share, one redeemable warrant, and one right to receive one-tenth of one Class A ordinary share [2]. - As of July 27, 2023, ATAK had 5,307,292 Class A Ordinary Shares outstanding and $56.7 million remaining in the Trust Account after redemptions [4]. - Total current assets amount to $27,723,000, including cash and cash equivalents of $3,244,000 [22]. - Total assets are reported at $36,500,000, reflecting a pro forma combined balance sheet [22]. - Total current liabilities stand at $44,062,000, after adjustments [23]. - Total liabilities are reported at $73,837,000, including various adjustments [23]. - The pro forma combined total liabilities and stockholders' equity was $36,500 thousand [24]. - The company reported a total of 7,659,431 Class A ordinary shares subject to possible redemption [26]. - The weighted average shares outstanding for Class A Common Stock is 34,544,936 for both the nine months ended December 31, 2023 and the year ended March 31, 2023 [44]. Business Combination - The Business Combination with Legacy DIH was approved on December 18, 2023, and closed on February 7, 2024, with Legacy DIH stockholders receiving $250 million in aggregate consideration [16]. - Legacy DIH stockholders may receive up to an additional 6,000,000 shares of New DIH Class A Common Stock based on performance milestones related to stock price [16]. - The Business Combination included a reverse recapitalization between ATAK and Legacy DIH, with a redemption of 4,815,153 Class A Ordinary Shares for $53.4 million [9]. - The Business Combination will be accounted for as a reverse recapitalization, with Legacy DIH treated as the accounting acquirer due to its larger revenue and voting interest [34]. - The redemption of 4,815,153 Class A Ordinary Shares is allocated to Class A Ordinary Shares and additional paid-in capital, totaling $53.4 million [40]. Financial Performance - Revenue for the nine months ended December 31, 2023, was $45,117 thousand, with a gross profit of $20,300 thousand [26]. - Total operating expenses for the same period were $22,434 thousand, resulting in an operating loss of $2,134 thousand [26]. - The net income (loss) for the nine months was $(3,155) thousand, with a basic and diluted net income (loss) per share of $0.02 [28]. - For the year ended March 31, 2023, revenue was $54,119 thousand, with a gross profit of $30,245 thousand [29]. - Total operating expenses for the year were $32,909 thousand, leading to an operating loss of $(2,664) thousand [29]. - The net income (loss) for the year was $(1,864) thousand, with a basic and diluted net income (loss) per share of $0.28 [31]. - Pro forma net loss for the nine months ended December 31, 2023 is $(5.656) million, resulting in a net loss per Class A Common Stock of $(0.16) [44]. Shareholder Information - Existing Legacy DIH equity holders represent 78% of total shares, totaling 26,950,000 shares [20]. - New DIH public shareholders account for 7% with 2,512,139 shares issued [20]. - The company has 3,454,494 shares of New DIH Class A Common Stock available for issuance under the Stock Incentive Plan [20]. - The Stock Incentive Plan established an equity pool equal to 10% of the number of shares of New DIH Class A Common Stock outstanding on a fully diluted basis [18]. - ATAK's shareholders approved multiple extension amendments, allowing additional time to complete the initial business combination, with significant redemptions occurring during these votes [3][4]. Liabilities and Expenses - Accounts payable decreased to $3,721,000 from $5,097,000 [22]. - Employee compensation liabilities reduced to $2,607,000, down from $3,155,000 [22]. - The company incurred interest expense of $(744) thousand for the nine months ended December 31, 2023 [27]. - The change in fair value of warrant liability was reported as $148 thousand [27]. - Estimated transaction-related costs to be incurred by ATAK and DIH after December 31, 2023 total $9.0 million, excluding previously recognized costs [42]. - The total transaction accounting adjustment amounts to $3.6 million, including various transaction costs and reclassifications [40]. Pro Forma Information - The pro forma financial information reflects Legacy DIH's activity for the nine months ended December 31, 2023, and ATAK's activity for the nine months ended September 30, 2023 [9]. - The unaudited pro forma condensed combined balance sheet as of December 31, 2023 reflects a $58.9 million cash reclassification from the Trust Account available for the Business Combination [38]. - The pro forma adjustments do not reflect any anticipated synergies or cost savings associated with New DIH [35]. - The unaudited pro forma financial information is based on preliminary estimates and may differ materially from final amounts recorded [35]. - The historical activity of Hocoma AG, which retained liabilities of $11.4 million, will be treated as a transfer of assets and liabilities under common control [41].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the year ended December 31, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from______to________ Commission File Number: 001-41250 | --- | --- | --- | |------------------------------------------------------------------------------------------|---------------------- ...

Core Insights - DIH Holding US, Inc. has completed its business combination with Aurora Technology Acquisition Corp., allowing DIH to trade on Nasdaq under the ticker "DHAI" for its Class A common stock and "DHAIW" for its warrants [1][2] - The company aims to leverage the cash from this business combination to expand its market presence and solidify its position as a leader in robotic and VR-enabled rehabilitation technology [1][2] Company Overview - DIH is focused on delivering innovative care solutions for patients with disabilities and functional impairments, integrating robotic and VR technologies with clinical insights [4] - The company is positioned as a transformative provider in a fragmented industry, aiming to consolidate various niche technologies [4] Leadership and Governance - The combined company will be led by Jason Chen as president and CEO, supported by a seasoned executive team and a diverse Board of Directors [3] - The Board includes notable members such as Lynden Bass, Dr. Patrick Bruno, Max Baucus, F. Samuel Eberts III, Ken Ludlum, and Cathryn Chen [3] Strategic Goals - DIH plans to expand its global commercial efforts by partnering with leading institutions worldwide to enhance the quality of rehabilitative technology available [2]

SAN FRANCISCO, CALIF., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Aurora Technology Acquisition Corp. (NASDAQ:ATAKU, ATAK, ATAKW, ATAKR))) (the "Company") announced today that its sponsor, ATAC Sponsor LLC (the "Sponsor"), has deposited an aggregate of $135,000 (the "Extension Payment") into the Company's trust account in order to extend the date by which the Company has to consummate a business combination from January 9, 2024 to February 7, 2024. The Extension Payment was loaned as a draw down pursuant to an unsec ...